Status:
COMPLETED
Effect of BMS-986165 on the Blood Levels of Metformin
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants.
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Healthy, as determined by having no clinically significant deviation from normal in medical history, physical examination, electrocardiograms, vital signs, and clinical laboratory determinations
- Body mass index of 18.0 kg/m\^2 to 32.0 kg/m\^2, inclusive, and body weight ≥ 50 kg, at screening
- Must agree to follow specific methods of contraception, if applicable
Exclusion
- \- Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
December 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04671953
Start Date
December 18 2020
End Date
March 30 2021
Last Update
November 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences - Lenexa
Lenexa, Kansas, United States, 66219